Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: A single-institution experience

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1447-1454

  Ulrickson, Matthew ^a   Aldridge, Julie ^b   Kim, Haesook T ^b   Hochberg, Ephraim P ^b   Hammerman, Peter ^a   Dube, Christine ^a   Attar, Eyal ^a   Ballen, Karen K ^a   Dey, Bimalangshu R ^a   McAfee, Steven L ^a   Spitzer, Thomas R ^a   Chen, Yi Bin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Autologous transplant; Busulfan; Lymphoma

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; URSODEOXYCHOLIC ACID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACTERIAL INFECTION; CANCER CENTER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; ENGRAFTMENT SYNDROME; ENTEROCOCCUS; FEMALE; FOLLOW UP; GENERAL HOSPITAL; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HEMORRHAGIC CYSTITIS; HUMAN; LARGE CELL LYMPHOMA; LENGTH OF STAY; LIVER VENOOCCLUSIVE DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROCOCCUS; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PARAINFLUENZA VIRUS 3; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; UNITED STATES;

EID: 70350619174     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.07.014     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
3. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554-2559.
4. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP Trial. J Clin Oncol. 2003;21:3918-3927.
5. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
6. Tiwari D, Gao F, Hidalgo J, et al. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007;40:671-675.
7. Snyder MJ, Johnson DB, Daly MB, et al. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study. Bone Marrow Transplant. 1994;14:595-600.
8. Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007;40:919-924.
9. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
10. Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007;40:19-27.
11. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008;14:59-66.
12. Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008;43:37-42.
13. Fernandez HF, Escalon MP, Pereira D, et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant. 2007;40:505-513.
14. Hanel M, Kroger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81: 96-102.
15. Stein RS, Greer JP, Goodman S, et al. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000;25:257-262.
16. Stiff PJ, Dahlberg S, Forman SJ, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens. A Southwest Oncology Group trial. J Clin Oncol. 1998;16:48-55.
17. Wadhwa PD, Fu P, Koc ON, et al. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant. 2005;11:13-22.
18. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770-777.
19. Ballester OF, Agaliotis DP, Hiemenz JW, et al. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Bone Marrow Transplant. 1996;18:9-14.
20. Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000; 25:1243-1248.
21. de Magalhaes-Silverman M, Lister J, Rybka W, et al. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant. 1997;19: 777-781.
22. Schiffman KS, Bensinger WI, Appelbaum FR, et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant. 1996;17:943-950.
23. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998;21:383-389.
24. Zaucha R, Gooley T, Holmberg L, et al. High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008;49:1899-1906.
25. Diez-Martin JL, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011-6014.
26. Fernandez H. The use of intravenous busulfan and cyclophosphamide as a conditioning regimen for non-Hodgkin's lymphoma. Presented at the ASBMT/CIBMTR Tandem Meetings. Honolulu: Hawaii; 2006.